Received Feb 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 3 | PE9G5 | — |
received an Adult Hep B vaccine instead of the pediatric dosage; received an Adult Hep B vaccine instead of the pediatric dosage; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 8-month-old female patient who received HBV (Engerix B adult) (batch number PE9G5, expiry date 19-MAY-2025) for prophylaxis. Previously administered products included Engerix B adult (received 1st dose of Engerix B adult on unknown date) and Engerix B adult (received 2nd dose of Engerix B adult on unknown date). On 23-JAN-2025, the patient received the 3rd dose of Engerix B adult. On 23-JAN-2025, an unknown time after receiving Engerix B adult, the patient experienced adult product administered to child (Verbatim: received an Adult Hep B vaccine instead of the pediatric dosage) and overdose (Verbatim: received an Adult Hep B vaccine instead of the pediatric dosage). The outcome of the adult product administered to child and overdose were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-JAN-2025 The reporter reported that a patient received an Adult Hepatitis B vaccine instead of the pediatric dosage, which led to adult product administered to child and overdose. Consented to follow up.